Relationship Between FGF19 Overexpression and Disease Prognosis
ConditionHepatocellular Carcinoma (HCC)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Tsinghua Chang Gung Hospital
About this trial
A real-world study of FGF19 overexpression status and treatment outcome and prognosis in advanced hepatocellular carcinoma
Eligibility criteria
Qualifiers
Age ≥18 years on the day of signing the informed consent form
Histologically or clinically confirmed diagnosis of intermediate to advanced HCC
Adequate tissue samples of previous liver cancer
Expected survival of more than 3 months
Disqualifiers
Fibrous laminae or sarcomatoid HCC or mixed HCC-ICC, or other rare non-HCC pathologic subtypes
Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate
Trial design
Treatments tested in this trial
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov